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Abstract: Optical technologies are essential for the rapid
and efficient delivery of health care to patients. Efforts
have begun to implement these technologies in miniature
devices that are implantable in patients for continuous or
chronic uses. In this review, we discuss guidelines for bio-
materials suitable for use in vivo. Basic optical functions
such as focusing, reflection, and diffraction have been re-
alized with biopolymers. Biocompatible optical fibers can
deliver sensing or therapeutic-inducing light into tissues
and enable optical communications with implanted pho-
tonic devices. Wirelessly powered, light-emitting diodes
(LEDs) and miniature lasers made of biocompatible mate-
rialsmayoffer newapproaches in optical sensing and ther-
apy. Advances in biotechnologies, such as optogenetics,
enable more sophisticated photonic devices with a high
level of integration with neurological or physiological cir-
cuits. With further innovations and translational develop-
ment, implantable photonic devices offer a pathway to im-
prove health monitoring, diagnostics, and light-activated
therapies.
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1 Introduction
Each year, more than 30 million of various medical de-
vices are implanted in the human body, extending and
improving the quality of lives of the patients. Among the
most implanted are intraocular lens (IOL), stents, artifi-
cial joints, cardiac pacemakers, and artificial cochlea. In
2014,more than 20million IOLprocedureswere performed
worldwide, replacing the natural crystalline lens in the
eye in cataract surgery. The development of IOLs was pio-
neered by Harold Ridley, who as a surgeon in World War
II, noticed that poly(methyl methacrylate) (PMMA) frag-
ments from shattered aircraft canopies that penetrated the
eyes of pilots remained biologically inert [1–3]. PMMA re-
mained the dominant material for IOLs for at least 40
years, until the advent of acrylics and silicone [4]. The de-
sign and materials are chosen based on the lens power as
required on a patient-specific basis. Commercial IOLs offer
a fixed refractive power, but future IOLs may incorporate
active elements for adaptive accommodation.
The artificial retina, or retinal prosthesis, is an opto-
electronic device that is implanted in the eye to restore
vision for people suffering from incurable blindness be-
cause of retinal degeneration, such as age-related macu-
lar degeneration and retinitis pigmentosa [5]. While the
photoreceptor cells for these patients are nonfunctional,
many of the inner retinal neurons remain functional and
can be electrically stimulated to elicit visual responses. A
number of retinal prostheses have been approved for hu-
man use [6, 7]. One such device, the Alpha IMS subretinal
implant, uses multiphotodiode arrays and electrodes that
sense light and stimulate the biopolar cells of the inner
retina [8]. Apower supply is needed for this device because
ambient light does not generate sufficient photocurrent to
stimulate neurons [9]. Recently, a significant improvement
over this design has been demonstrated in rats, in which
silicon photodiodes are simultaneously powered and ac-
tivated by pulsed near-infrared (NIR) illumination deliv-
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ered by video goggles, obviating the need for an additional
power supply [10, 11].
Beyond these ophthalmic applications, photonic and
related technologies for other medical applications have
beendeveloped. To fulfill thepromise of real-timediagnos-
tics and sensing, as well as chronic light delivery to deep
tissues, photonic devices are increasingly designed with
biocompatible and implantable properties. Devices made
from biocompatible materials can be left in the body for
prolonged periods of time and used for long-term health
monitoring and therapeutics. Direct integration of pho-
tonic components into living tissue can enhance light–
tissue interactions, enabling new applications in sensing
and light generation. Many existing passive (light guid-
ing, refraction, diffraction, etc.) and active (light genera-
tion and detection) optical device functions can be real-
ized by using biocompatible materials.
Here, we overview recent developments in im-
plantable photonic devices. First, we review the require-
ments and challenges associated with biocompatibility
when devices are implanted in the human body. Next,
we describe progress toward biocompatible photonic de-
vices, including passive devices and light sources. Pas-
sive devices include waveguides, lenses, diffractive and
holographic components, reflectors, photonic crystals,
and plasmonic devices. Active devices are light sources,
which include incoherent light-emitting diodes (LEDs) or
coherent lasers. We also describe photonic devices that
use these functional elements. Fluorescent probes, single
plasmonic nanoparticles, and light-activated drugs are
reviewed elsewhere [12–16].
2 Biocompatibility Requirements
Photonic technologies arewell suited for biomedical appli-
cations because of the potential of rapid, precise, and non-
invasive or minimally invasive control of biological con-
stituents in the body. While many of these capabilities
have been demonstrated in vitro, biocompatibilitymust be
considered when designing photonic devices for implan-
tation in vivo. Biocompatibility of a material refers to not
only the absence of cytotoxicity and minimal health risks
for the patient but also the biofunctionality of thematerial
that enables the device to perform its desired function in
an implanted position [17, 18]. In this section, we overview
the key design criteria of implantable photonic devices,
the tissue reactions induced by implantation of these de-
vices, and strategies to overcome the challenge of achiev-
ing biocompatibility while maintaining functionality.
2.1 Biocompatible and Biodegradable
Materials
The implanted device should integrate with the human
body while minimizing tissue reactions that could be
harmful for the patient or impair the functionality of the
device. Generally, the device is desired to be biodegrad-
able, which would eliminate the need for a follow-up pro-
cedure to retrieve thedevice.Materials that havebeenused
for implantable devices include natural and synthetic ma-
terials and hydrogels (Table 1) [17, 19–22].
Natural materials derived from organisms, such as
collagen, silk fibroin, and alginate, can be recognized
metabolically by the host and be degraded by proteolytic
enzymes. The degradation rate of these materials varies
significantly depending on the implant location and avail-
ability of degradative enzymes [23]. However, biologically
derived materials may tend to suffer from batch-to-batch
variability, restricted range of mechanical properties, pos-
sible immunogenicity, and risk of infection by contamina-
tion of bacteria, viruses, or prions [18, 23–26].
Synthetic polymers can be designed to have specific
material properties but biocompatibility is a challenge
because of the foreign body reaction (FBR) [27]. Exam-
ples of synthetic polymers include poly(lactic acid) (PLA),
poly(lactic-co-glycolic acid) (PLGA), and poly(ethylene
glycol) (PEG) [21–23, 28]. Hydrolytically degraded poly-
mers, such as polyesters, may be preferred for implantable
devices because of less patient-to-patient variability as
compared to the enzyme-catalyzed degradation of natural
polymers [23, 29]. The biodegradation mechanisms of var-
ious biodegradable polymers are reviewed elsewhere [23,
28–30].
Several photonic devices use inorganic materials,
such as gold, silicon, and compound semiconductors such
as indium gallium nitride (InGaN). While these materials
are not biodegradable, their biocompatibility varies de-
pending on the material, device size, mechanical proper-
ties, and the presence of coatings. Silver (Ag) nanoparti-
cles (3–100 nm) are toxic at all sizes, attributed to oxida-
tive stress caused by Ag+ ions, while gold nanoparticles
are generally considered nontoxic at low concentrations
(< 0.5 mg/kg daily) at sizes of 3–100 nm [31–33]. While
Cd2+ ions released from CdSe quantum dots are highly cy-
totoxic, polymer coated or ZnS shell quantum dots signifi-
cantly improve biocompatibility [34]. Gallium nitride is an
emerging biocompatible semiconductor for use with neu-
ral interfaces [35]. In a recent study, silicon transistors, In-
GaN, and AlInGaP semiconductor LEDs integrated on low
modulus silicone substrates had minimal cytotoxicity and
no immunogenicity after four weeks of subcutaneous im-
Brought to you by | MIT Libraries
Authenticated
Download Date | 5/19/17 2:25 PM
416 | Matjaž Humar and Sheldon J.J. Kwok et al., Toward biomaterial-based implantable photonic devices
plantation in mice [36]. These flexible and stretchable de-
vices enabled accommodation of natural movements, re-
ducing the risk of inflammation and damage caused by
mechanical motion.
When selecting materials for implantable photonic
devices, biocompatible properties must be considered
alongside the functional requirements, such as structural
stability and optical clarity. Mechanical flexibility is also
an important characteristic that facilitates noninvasive in-
tegration of the device with tissue. An example of a ma-
terial that meets these requirements is silk fibroin, a pro-
tein that has been used for biophotonic applications be-
cause of its optical transparency and implant compatibil-
ity [19]. Silk films canalso be generatedwith features down
to tens of nanometers in size, which is ideal for optical ap-
plications such as diffraction gratings. Silk has been used
to create various biocompatible optical devices, including
microlens arrays, microprism arrays, and diffraction grat-
ings [19, 37–39].
Another class of biocompatible materials are
hydrogel-based materials, such as with PEG and
poly(vinyl-alcohol) (PVA) [40, 41]. Hydrogels are three-
dimensional polymeric networks that retain water, mim-
icking the body’s extracellular matrix (ECM) [40] and are
commonly used for tissue engineering applications [41].
They offer unique advantages such as tunable material
properties, the possibility of incorporating chemical func-
tional groups, and the ability to encapsulate drugs or
cells [21, 40, 41]. For sensing applications, the degree of
analyte diffusion through the hydrogel can be controlled
by varying the cross-linking density of the gel [17]. How-
ever, the mechanical properties of hydrogels, such as low
tensile strength and poor adhesion to substrates, make
them unsuitable for some applications [18]. By varying the
water content or monomer size, the optical transparency
of PEG hydrogels can be optimized for light-guiding appli-
cations [42, 43].
An emerging class of photonic devices uses living tis-
sues and cells as optical elements, offering the possibility
of a biocompatible, reagent-free, and self-healing platform
for photonic devices. Such optical devices could repair it-
self upon damage. Self-healing and regeneration also have
drawbacks because the properties of the living optical de-
vice change with time and can produce nonreproducible
results. On the other hand, these changes can also be used
as a sensor providingdirect opticalmeasurement of the liv-
ing constituents of the device. The properties of living ma-
terials may not be changed substantially without compro-
mising their viability. The majority of tissues have strong
light scattering and absorption, which greatly limits the
light propagation. Scattering in rare cases can be benefi-
cial, for example, in random lasers, which require strong
scattering for their operation [44–47].
The use of live cells is particularly effective when
rendered photonic functionalities by genetic engineering;
for example, fluorescent proteins for use as a laser gain
medium [48–50] or optogenetic proteins for sensing or in-
ducing synthesis of therapeutic hormones [42]. Natural
optical cavities formed by lipid droplets inside adipocyte
cells have also been demonstrated [47]. For implantable
devices, living cells will likely need to be incorporated into
tissue using a substrate capable of sustaining them, such
as a hydrogel matrix. Furthermore, the cells should ideally
be taken directly from the host to prevent any adverse im-
mune response [51].
2.2 Inflammatory and Foreign Body
Responses
The biological response of the human body to implanted
devices is a major technical challenge [17]. This response
can be classified into three stages [17, 21, 27]: acute inflam-
mation, chronic inflammation, and foreign body response
(FBR). The first two stages reciprocate what occurs during
normal tissue injury and healing, but the continued pres-
ence of the device in the body leads to the FBR.
The initial, acute inflammatory process is caused by
adsorption of host proteins to the implant surface and tis-
sue injury caused by the implantation or injection pro-
cess. This phase, lasting a few days, is characterized by
neutrophil infiltration and release of proteases and oxy-
gen free radicals to degrade the foreign body. During the
chronic inflammation phase, neutrophils are replaced by
monocytes and lymphocytes, which induce the formation
of new blood vessels and connective tissue. This phase
typically lasts several weeks [28]. While in normal wound
healing, chronic inflammation eventually resolves, the
FBR follows chronic inflammation when a foreign body is
continually present.
This FBR is characterized by the formation of for-
eign body giant cells, which result from the fusion of
macrophages. The characteristic end stage of the FBR in-
volves the fibrous encapsulation of the device by an avas-
cular, collagenous capsule that is typically 50–200 µm in
thickness [52]. The degree of fibrous encapsulation de-
pends on a number of factors, including the properties of
the implanted material, surface chemistry and roughness,
and implant duration and location [53]. The physiological
state of the tissue, suchasdiseasedor inflammatory states,
can also modulate the degree of FBR [54, 55].
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Table 1. List of selected biomaterials that have been used in implementable photonic devices.
Material Biocompatibility & Biodegradability Optical property Application
Silk Biocompatible and biodegradable
with a lifetime in the order of years
Transparent dielectric material Waveguides [38, 51], gratings [37,
52, 53], photonic crystals [54],
reflectors [36], lasers [55], sub-
strate [56]
Poly(ethylene glycol)
(PEG) hydrogel
Biocompatible, can be biodegradable Transparent dielectric material Waveguides [41, 42]
Agarose hydrogel Biocompatible Transparent dielectric material Waveguides [57, 58]
Polylactic acid (PLA) Biocompatible and biodegradable
with a lifetime in the order of months
Transparent dielectric material Waveguides, substrate [59]
Poly(lactic-co-glycolic
acid) (PLGA)
Biocompatible and biodegradable
with a lifetime in the order of weeks
Transparent dielectric material Waveguides [60]
Poly(methyl methacry-
late) (PMMA)
Biocompatible Transparent dielectric material Intraocular lens [1–3]
Cells Endogenous Laser gain material Lasers [46, 47, 61–63]
Bacteria Somestrains in symbiosiswithhuman
body
Laser gain material Waveguides [64], lasers [49, 65]
Fluorescent proteins Biocompatible and biodegradable Laser gain material Lasers [47, 66–69]
Riboflavin Endogenous Laser gain material Lasers [55, 59, 70]
Silver and gold Biocompatible Plasmonic effects Plasmonic sensors [12–14, 56, 71]
Lipids Endogenous Transparent dielectric material Gratings [72], lasers [46]
Other non-fluorescent
proteins
Endogenous Transparent dielectric material Waveguides [73], gratings [74, 75]
Biological tissues Endogenous Scattering material Random lasers [43–46]
DNA Endogenous Matrix for active molecules Lasers [76–80], LEDs [81–84]
Cellulose Biocompatible and biodegradable Transparent dielectric material Waveguides [85], substrate [86]
Few studies have systematically studied the effect of
material size and geometry on the FBR. A recent study
tested the long-term implant compatibility of spherical
materials with diameters ranging from 0.3 to 1.9 mm in
rodents and monkeys [56]. While spheres smaller than
0.5 mm had severe fibrotic responses, spheres of 1.5 mm
or larger diameters had significantly diminished FBR and
were largely devoid of cellular deposition even after six
months of implantation. This effectwas restricted to spher-
ical shapes and independent of surface area and mate-
rial composition, which included alginate, stainless steel,
glass, polycaprolactone, and polystyrene. These findings
suggest that the in vivo biocompatibility of implanted de-
vices can be significantly improved by simply increasing
their spherical dimensions, but the underlying mecha-
nisms remainunclear andare thought tobe related tomod-
ulation of macrophage recruitment and polarization. Sys-
tematic studies need to be undertaken to understand the
FBR to a wider range of shapes and sizes of materials im-
planted in different locations.
For applications involving smaller devices, micro-
spheres greater than 5 µm in diameter are known to elicit
anFBR,while smallermicrospheresmaybephagocytosed,
which can accelerate their biodegradation [28]. As the di-
ameter of a spherical particle is decreased, the surface-to-
volume ratio increases, which enhances the surface reac-
tivity [57]. For nanoparticles, the surface layer of adsorbed
proteins, often called the “protein corona,” is a key deter-
minant of its biological andmetabolic fate in vivo [58]. The
biocompatibility and toxicity of nanomaterials have been
comprehensively reviewed elsewhere [57–61].
The inflammatory response, FBR, and fibrous encap-
sulation cannegatively impact the function of implantable
medical devices. The device must be able to function in
a potentially compromised environment because of the
presence of degradative enzymes, reactive oxygen species,
and acidic conditions, as low as pH 3, caused by the in-
flammatory process [27, 28]. Furthermore, the fibrous cap-
sule can be severely limiting,which is particularly the case
for in vivo biomolecule sensing [62]. The capsule prevents
the transport of analytes, such as glucose, to the sensor
surface, resulting in a decrease of sensor functionality fol-
lowing implantation. Another challenge is calcification of
the implanted device, which can occurwith cell injury and
accumulation of cellular debris following long-term im-
plantation [17]. Calcification is amajor issue that limits the
lifetime of bioprosthetic heart valves.
A number of strategies have been explored to mini-
mize the FBR [63]. One approach is using locally delivered
drugs to modulate the inflammatory response. Glucocorti-
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coids, such as dexamethasone, can inhibit inflammatory
mediators leading to reduced fibroblast proliferation and
fibrous encapsulation [18, 21, 64]. Angiogenic drugs that
enable reperfusion of the capsule have also been used to
improve the functional lifetime of biosensing devices [65].
Improving blood flowwithin the capsule can also enhance
transport of analytes to the sensor surface [66]. Another
study showed that implantswith uniform, highly intercon-
nected 34-µmpores increasedvascularizationand reduced
fibrosis compared to a nonporous implant of the same bio-
material [67].
A particularly successful approach is to minimize the
adsorption (“fouling”) of nonspecific protein, which trig-
gers and sustains inflammation, to the device [21]. Various
nonfouling coatings using hydrophilic materials, such as
PEG, PLA, or hydrogels, have been used to encapsulate the
device, reducing inflammation andfibrosis [18, 66, 68]. Re-
cently, ultra-low-fouling zwitterionic hydrogels implanted
subcutaneously in mice for three months were found to
resist the formation of a fibrous capsule and promote an-
giogenesis in the surrounding-healing tissue [63, 69]. The
zwitterionic hydrogels were synthesized from pure car-
boxybetaine materials, which because of their repulsive
hydration forces are resistant to nonspecific protein ad-
sorption [70].
To ensure that a given device is biocompatible, the lo-
cal and systemic effects of the implanted device must be
tested. The International Organization for Standardization
(ISO) 10993 provides a series of guidelines, including in
vitro and in vivo test procedures [17, 25]. These include tests
for cytotoxicity, irritation, sensitization, carcinogenicity,
hemocompatibility, and systemic toxicity [71].
2.3 Other Safety Considerations
Aside from the FBR, there are other practical challenges
that should be considered. First, sterilization techniques
such as ethylene oxide (EtO) sterilization, gamma radi-
ation, and E-beam sterilization are necessary before im-
plantation to remove harmful microorganisms [72]. The
device must be able to withstand these sterilization pro-
cesses without impairing functionality; for example, silk
fibroin can be sterilized using EtO, gamma radiation, or
70% ethanol, while collagen cannot be sterilized under
these conditions [73].
Second, power delivery is an important consideration
for active photonic devices such as implantable LEDs. To
avoid the need for an implantable battery thatmay need to
be replaced, wireless power transmission would be ideal
for the patient. Recently, a method for efficient wireless
power transfer using mid-field frequencies enabled more
than 2mW of power to be delivered to deep tissues around
5 cm from the source [74]. This power was delivered at the
maximumsafety standards of 10W/kg of tissue [74, 75] and
is sufficient to power a whole host of implantable devices
including miniature LEDs [76].
A final concern, which is unique to photonic devices,
is unintended phototoxicity to cells. This could occur if
high optical powers are used, for example, to compensate
for optical loss in the system, light is focused accidentally
to a small area, or if phototoxic ultraviolet (UV) light is
needed to form the device, such as UV-cross-linking of in
situ forming hydrogels [40]. The primary mechanisms of
light damage to cells are photothermal and photochemi-
cal [77, 78]. Photothermal damage occurs due to light ab-
sorption leading to an increase in temperature which can
cause denaturation of deoxyribonucleic acid (DNA) and
proteins above 67 °C [78]. Importantly, the photothermal
damage threshold increases for longer exposure time be-
cause heat dissipates over time and space. Photochem-
ical damage is mediated by cellular chromophores that
cause the generation of free radicals that cause cellular in-
jury [77]. The International Commission on Non-Ionizing
Radiation Protection (ICNIRP) provides guidelines on ac-
ceptable limits of exposure to laser radiation, depending
on wavelength and duration [79].
3 Optical components
We describe passive optical components made of biocom-
patible materials. These optical elements include diffrac-
tion gratings, photonic crystals, reflectors, plasmonic de-
vices, and photodetectors, which are well-established
components traditionally made with inorganic materials,
such as glasses, metals, and semiconductors.
3.1 Diffraction grating reflectors
Diffraction gratings are mostly used for spectroscopic ap-
plicationswhere they redirect light depending on itswave-
length. Diffraction gratings made with materials that are
sensitive to specific analytes can be used for sensing. An
analyte of interest can change the diffraction efficiency or
the grating period, and thus can be detected bymeasuring
the change in the intensity or spectrum of diffracted light.
A diffraction grating has been fabricated with self-
assembled lipid multilayers by using parallelized dip-pen
nanolithography to deposit 5–100 nm high lines onto a
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solid substrate (Fig. 1) [80]. These gratings enabled sens-
ing of proteins with sensitivity down to 5 nM by their inter-
calation into lipid multilayers, which lowered diffraction
efficiency of the gratings.
h = 5 − 100  nm
d >100 nm
h
d
Lipid 
ink
DPN tip
Fig. 1. Dip-pen nanolithography used to fabricate lipid multilayer
gratings. Reprinted by permission from [80], Copyright 2010,
Macmillan Publishers Ltd.
Silkhasbeenapopularmaterial for fabricationof opti-
cal diffractive elements [38, 81, 82]. Gratings are produced
by pouring silk fibroin solution to a master mold, allow-
ing it to dry, and detaching the silk layer to form a free-
standing grating. A silk grating was shown to have a sen-
sitivity in the refractive index change of n = 0.007, which
corresponds to a glucose concentration of 5% [83]. In an-
other demonstration [84], the matrix silk was mixed with
hemoglobin lysed from red blood cells, and the diffrac-
tion intensity depended on the absorption induced by oxy-
genation. Diffraction gratings and the Fresnel lenses with
desired patterns can be manufactured by photopolymer-
ization of silk conjugates with a photoinitiator [85, 86].
The microstructures can be produced in reasonably large
(>1 cm) areas. The fabricated structures have similar or su-
perior mechanical properties to native silk fibroin and can
readily interface with live cells [85]. Another study used
femtosecond laser direct writing to fabricate diffraction
gratings in protein films [87, 88]. Bovine serum albumin
was coated to a polydimethylsiloxane substrate and a 120-
fs titanium–sapphire laser was used to cross-link the pro-
tein to form a grating structure.
Silk has also been used to fabricate a microprism
retroreflector array (Fig. 2). This device was biodegradable
and has been implanted subcutaneously in mice [37]. In
vivo tests in mice showed up to a threefold enhancement
in reflectivity of bare tissue, which would be beneficial for
imaging and sensing. Gold nanoparticles and chemother-
apeutic drugs were also incorporated into the silk material
making a multifunctional device.
silk reflector
5 mm
A CB
Fig. 2. (A) SEM image of a silk microprism reflector. (B) A microprism
array prepared for implantation. (C) The reflector is implanted below
mouse skin in the dorsal area. Reprinted from [37], Copyright (2012)
National Academy of Sciences, USA.
3.2 Photonic crystals
Similar to diffraction gratings, photonic crystals can be
implanted into biological tissues and used for sensing
applications [89]. Change in the periodicity or refractive
index of the photonic crystal will change the spectrum
of reflected light. Further, photonic crystals can provide
distinct spectral signatures that could be used as con-
trast agents without the need for fluorescent tags. Pho-
tonic crystals are most frequently made by self-assembly
of colloidal particles or by laser recording. For example,
monodisperse and highly charged polystyrene and PMMA
particles self-assemble into a body-centered cubic or face-
centered cubic latticewith amesoscopic periodicity of 0.1–
1.0 µm [90, 91]. Photonic crystals have been also fabri-
cated using laser by silver halide chemistry [92], laser ab-
lation [93], or photopolymerization [94].
Photonic crystals can incorporate functionalized hy-
drogels which when coming into contact with a target an-
alyte, the volume of the hydrogel changes due to variation
in Donnan osmotic pressure. The volumetric alteration of
the photonic crystal shifts the bandgap to longer or shorter
wavelengths depending on the concentration of the tar-
get analyte. The change in the reflection can be measured
through the skin or by an optical fiber with reflection spec-
trometer and correlated with the concentration [95]. Pho-
tonic crystals can be functionalized to become sensitive to
a wide range of physiologically relevant analytes such as
Pb2+ ions [96, 97], urea [98], glucose [99], creatinine [100],
and ammonia [101] andpH in the physiological range (4.5–
9.0) [102, 103]. Glucose sensing with photonic crystals has
been demonstrated with a detection limit of ~100 µM in
the solution [104] and tear fluid [105]. In one study, the ef-
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ficacy of the sensors was tested in an in vivo trial by subcu-
taneous implantation below an eye of a rabbit [104]. In a
clinical trial, the photonic crystal integrated on a contact
lens was placed beneath the pupil of a human volunteer
and the concentration of glucose was monitored after glu-
cose administration [106]. As the concentration of glucose
in blood increased from 90 to 140 mg/dL, the holographic
sensor produced a 40-nm shift in the reflection peak. Re-
cently, photonic crystals sensors fabricated with chitosan
hydrogels have been demonstrated, which is operated in
the NIR spectral range [107]. Photonic crystals can poten-
tially be incorporated in hydrogel-based ocular inserts or
contact lens sensor for patients with diabetes [108].
Three-dimensional photonic crystals have been fab-
ricated entirely out of silk (Fig. 3) [109]. The silk inverse
opals show iridescence or structural color when covered
with biological tissue, whichmay be used for refractive in-
dex measurement and for targeted laser-induced heating
through photonic crystal-enhanced absorption.
Fig. 3. Silk inverse opals showing structural color. Reprinted by
permission from [109], Copyright 2012, Macmillan Publishers Ltd.
3.3 Plasmonic devices
Some applications can benefit from nano- or microscale
devices. Plasmonics [110] offers practical ways to minia-
turize devices by providing enhanced absorption and
scattering properties by optical coupling with free elec-
trons. The use of plasmonic nanoparticles for diagnos-
tic imaging and photothermal therapy have been exten-
sively explored [111–113]. Several photonic devices in-
corporating plasmonic nanoparticles have been demon-
strated. Gold nanoparticles and chemotherapeutic drugs
were incorporated into a silk multifunctional polymer
device [37]. A biocompatible nanoplasmonic device was
assembled with the aid of programmable DNA assem-
bly [114], which can control the chirality of plasmonic
nanostructures (Fig. 4) [115, 116]. A 3D photonic crystal of
DNA-labeled plasmonic nanoparticles was fabricated by
DNA-programmable crystallization with nanometer preci-
sion [117]. In another approach, plasmonic nanoparticles
are used to optically sense DNA molecules in complex
media, where binding of the target DNA causes a spatial
extension of the plasmonic nanoparticle dimer inducing
spectral shifts [118]. A variety of plasmonic nanostructures
such as nanodot, nanohole, and bowtie patters were first
fabricated on a silicon substrates and sequentially trans-
ferred to a silk substrate [119]. These plasmonic structures
can be used as sensors or to enhance fluorescence [120].
A spectral shift sensitivity up to 1200 nm/RIU has been
demonstrated for sensing glucose [121].
RCP
LCP
  
Fig. 4. DNA-based self-assembly of chiral plasmonic nanoparticles.
Reprinted by permission from [114], Copyright 2012, Macmillan
Publishers Ltd.
3.4 Photodetectors
A photodetector converts light energy to an electrical sig-
nal. Most studies on photodetectors have been focused on
applications related to retinal prosthetics. Recent efforts
have been devoted to develop photodetectors with im-
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proved conversion efficiency, mechanical flexibility, and
biocompatibility over conventional photodiodes based on
inorganic silicon. Organic semiconductors, particularly
conjugated polymers (CPs), have shown promise as a po-
tential alternative to silicon [122]. CPs interact with light
through conjugated pi-electrons, just like natural photore-
ceptors. Compared to traditional approaches using mul-
tiple inorganic elements and electrodes, the promise of
a single-component, all-organic, wireless artificial retina
that does not require external electrical power is enticing.
CPs produce negligible heat and are flexible [123, 124]. Ad-
ditionally, organic retinal prosthesis based on CPs have
been demonstrated [125–127], although their in vivo bio-
compatibility and functional lifetime have yet to be estab-
lished. Besides the retina, biocompatible photodetectors
maybe implanted in thebody for optical sensingand imag-
ing. The optical signal is detected and converted to an elec-
tronic signal, which can then be transmitted wirelessly to
an external receiver.
4 Waveguides and
waveguide-based devices
Optical implantable waveguides are potentially useful for
delivering therapeutic light deep into target tissues and for
delivering light to and from other implanted photonic de-
vices.While optical waveguides based on silica fibers [128]
or silicon oxynitride planar waveguides [129] in various
forms have been implanted in animals, particularly for op-
togenetic studies in the brain [130], low-loss waveguides
can be made from a variety of biocompatible, transpar-
ent materials. For low guiding loss, the refractive index of
the biomaterial should be higher than that of adjacent tis-
sues, which ranges typically from 1.34 (interstitial fluid) to
1.47. For some applications, however, the light-guiding ef-
ficiency is deliberately reduced so that light is extracted
to the surrounding tissue through the waveguide surface
along the length. Furthermore, optical waveguides may
incorporate functional materials, such as dyes, photoac-
tivable chemicals, nanoparticles, and live cells, within the
core, cladding, and/or external surface of the waveguide
to add a variety of photonic functionalities useful for sens-
ing and therapy. Beside surgical implantation,waveguides
may be injected using needles and formed in situ using
materials, such as guest–host–assembly hydrogels or ther-
moresponsive hydrogels [131].
4.1 Bio-derived material waveguides
Several bio-derived polymers are good candidates for im-
plantable waveguides. A cellulosewaveguide has been de-
veloped using cellulose butyrate fibers (refractive index,
n = 1.475) as a core and hydroxypropyl cellulose powder
(n = 1.337) as a cladding, with a relatively low propaga-
tion loss of ~1 dB/cm [132]. The porous cladding layer
can serve as a microfluidic channel for drug delivery and
biosensing. Silk has a refractive index (n = 1.54) higher
thanmost tissues. Silk optical waveguides were fabricated
on a glass substrate [39], on a biocompatible substrate, or
as free-standing fibers, with propagation losses as low as
0.25 dB/cm. Native spider silk filament has been shown to
guide light, albeit at high loss up to 10.5 dB/cm [133].
Optical waveguides may also be made of endogenous
proteins and peptides extracted from host tissues. For ex-
ample, long needle-like peptide crystals self-assembled
from diphenylalanine can guide light and emit fluores-
cence [134].
It has been demonstrated that a linear array of
Escherichia coli aligned by optical forces could guide
light [135]. Although bacteria would not be considered ap-
plicable to implantable devices, this work suggests the
possibility of forming an optical waveguide in situ inside
biological tissue by self-assembly of human cells or bio-
compatible particles.
4.2 Biodegradable synthetic polymer
waveguides
Several biodegradable synthetic polymers are used for
medical implants and could alsobeused for opticalwaveg-
uides. Planar waveguides were fabricated from PLA and
PLGA by first press melting a material to form a transpar-
ent film and then using laser cutting to make arbitrary
shapes [136]. The waveguides were connected to a conven-
tional optical fiber (Fig. 5a), and green laser light was de-
livered deep into the skin tissue (Fig. 5b). The light propa-
gation and waveguide loss was tailored by the waveguide
shape, so that the light was extracted uniformly along the
implantation site (Fig. 5c). Biodegradation of PLGAwaveg-
uides tested in vivo showed good waveguide transparency
in the first week, with loosing of transparency in two or
three weeks and complete biodegradation and reabsorp-
tion by the body within five weeks (Fig. 5d).
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Fig. 5. Biodegradable synthetic polymer waveguides. (A) Planar
comb-shaped PLA optical waveguide connected to an optical fiber.
(B) Delivery of light through the waveguide deep into the skin tis-
sue. (C) Photobleaching of an applied dye indicates the area of light
penetration. (D) Biodegradation of a piece of PLA waveguide in vivo
during 35 days. Reprinted by permission from [136], Copyright 2016,
Macmillan Publishers Ltd.
4.3 Hydrogel waveguides
Hydrogels are commonly used in tissue engineering be-
cause of their ability to encapsulate cells, serving as scaf-
folds for tissue repair and regeneration. Their high wa-
ter content mimics tissue properties, limiting FBR, and
they can be readily functionalized with biologically ac-
tive materials that can be interfaced with living tissues.
An agarose gel (2%, w/v) waveguide containing live cells
has been fabricated by soft lithography on top of agarose
gel substrates (Fig. 6a) [137]. The difference in the concen-
tration of agarose caused the waveguides to have slightly
higher refractive index (n = 1.3357) than the substrate (n =
1.3343) guiding light with an average loss of 13 dB/cm. Hy-
drogelwaveguideswere integrated in amicrofluidic device
composed entirely of agarose gels [138]. A waveguide were
fabricated by spin coating low index (n= 1.497) agarose hy-
drogel at both sides of a high index (n = 1.536) gelatin layer
(Fig. 6b).
Cylindrical optical fibers have been fabricated with
high-index PEG hydrogels for the core and lower index al-
ginate hydrogels for the shell (Fig. 7a). These biocompat-
ible hydrogel optical fibers had a low propagation loss of
0.42 dB/cm over a fiber length of 1 m. In addition, the per-
meable nature of the hydrogel materials enabled facile in-
corporation of small-molecular dyes (Fig. 7b) or nanoparti-
cles to incorporate various functionalities to the fiber, such
as plasmonic photothermal heating and light amplifica-
tion [43]. The flexibility and biocompatibilty of the fibers
may be suited for in vivo applications (Fig. 7c).
A
B
Fig. 6. Hydrogel waveguides. (A) Live cells encapsulated in an
agarose hydrogel waveguide. Reprinted by permission from [137],
Copyright 2012, The Optical Society. (B) Light guiding in core-
cladding hydrogel waveguide. Reprinted by permission from [138],
Copyright 2009, Wiley.
Fig. 7. Hydrogel-based optical waveguide. (A) Light guidance of a
fiber in a tissue ex vivo. Scale bar, 1 cm. (B) A fluorescence image of
a fiber doped with three different fluorophores along the fiber, as
indicated. (C) In vivo light guidance through a hydrogel fiber admin-
istered to the colon through the rectum. Reprinted by permission
from [43], Copyright 2015, Wiley.
4.4 Light-guiding hydrogel implants
Hydrogels can be used as photonic materials for guiding
light by optimizing their chemical compositions [42]. With
an optimal recipe to achieve high transparency and me-
chanical flexibility, a hydrogel encapsulating cells have
been fabricated in a form of slab waveguide. A pigtail
optical fiber establishes an efficient optical communica-
tion to the cells within the hydrogel (Fig. 8a). Genetically
altered HeLa cells that respond to cellular stress by ex-
pressing green fluorescent protein (GFP) were implanted
subcutaneously in a mouse for sensing of nanotoxicity in
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vivo. Sensor signal increased when CdTe quantum dots
were intravenously injected, but no change was observed
with core/shell CdSe/ZnS quantum dots, confirming the
role of the ZnS shell in reducing cytotoxicity. In another
demonstration, HeLa cells engineered to produce antidia-
betic hormone GLP-1 in response to blue light [139] were
seeded in a hydrogel waveguide. When implanted in di-
abetic mice, treatment with blue light significantly im-
provedblood-glucose homeostasis (Fig. 8b). Hydrogels im-
planted for eight days remained largely functional, with
less than 1 dB cm−1 loss in optical transmittance, andwith
more than 65% of the embedded cells remaining viable. A
mild FBR was also observed, with the formation of loose
connective tissues around the implant. Future research
optimizing the light-guiding properties, cell implantation,
and FBR-resistant properties [69] may lead to the devel-
opment of practical, chronically implanted hydrogels for
sensing and therapeutic applications.
Optical excitation
Return signals
Light-guiding
hydrogel implant
Sensing cells/
therapeutic cells
Tissue in vivo
A B
Fig. 8. Hydrogel-based active optical waveguiding devices. (A) A
schematic for the cell-integrated optical waveguide. (B) A hydrogel-
implanted mouse in a freely moving state with a blue light coupled.
Reprinted by permission from [42], Copyright 2013, Macmillan Pub-
lishers Ltd.
5 Bio-Lasers
Bio-lasers represent an emerging class of light sources
where laser light can be generated in situ in target cells and
tissues. As with all lasers, three components are needed:
an optical cavity that confines light, a gain medium that
amplifies light in the cavity, and pump energy to power
the gain medium. Bio-lasers implanted or injected in tis-
sue can serve as a local light source in imaging, diagnosis,
and therapeutic applications.
5.1 Fluorescent protein and organic dye
lasers
Fluorescent proteins (FPs), derived from aquatic organ-
isms such as jellyfish, are widely used as reporters of gene
expression in animal models. FPs have high extinction co-
efficients (20,000–140,000M−1cm−1), good photostability,
and high quantum yields of 0.6–0.8 [140]. The lasing of
FPs has been demonstrated in different cavity configura-
tions.GFP in a solution [148] or as adried thinfilm [141, 142]
placed in between twomirrors were shown to provide high
optical gain supporting laser generation at low threshold
energy down to 100 pJ. A GFP ring laser with 1–2 mm in di-
ameter formed by drying a droplet of GFP on a surface was
demonstrated [142]. In another study, DsRed2 was embed-
ded inside a layered high-scattering medium acting as a
random one-dimensional cavity [143].
As an alternative to fluorescent proteins, small
molecules with pi-conjugated fluorophores found natu-
rally in human tissues can be exploited as a gain mate-
rial for biocompatible photonic devices. Vitamin B2 (ri-
boflavin) has the highest quantum yield of 0.23 among
themolecules present in the human body [144]. Riboflavin
was used as a gain medium in a water–glycerol micro-
droplet whispering-gallery (WG) laser [145]. Riboflavin-
doped droplets were generated on a superhydrophobic
surface having nearly spherical shape. To prevent evapo-
ration and droplet collapse when implanted into a biolog-
ical tissue, the droplets were encapsulated in biodegrad-
able PLA microwells. A single-mode distributed feedback
laser made from riboflavin-doped gelatin was demon-
strated using a micro-patterned, nonbiocompatible poly-
mer substrate with a low refractive index (n = 1.39) [146].
An extension of this design was composed entirely on
biocompatible materials including silk [147].
DNA has been used to enhance the functionality of or-
ganic dye lasers. Intercalation of dye molecules in DNA
strands allowed for dye loading at high concentration
and reduced fluorescence quenching, which lowered the
threshold for amplified spontaneous emission and las-
ing [148]. Lasing has been reported in a thin film of DNA
doped with Rhodamine 6G dye [149] and in distributed
feedback cavities containing DNAs dopedwith fluorescent
dyes [150, 151]. DNAwas used as a linker of a donor and ac-
ceptor fluorescent dyes in an optofluidic laser as a means
to control the efficiency of the Förster resonance energy
transfer (FRET) between the gainmolecules [152]. The con-
formational change of the DNA linker by external factors
affects the laser output characteristics, such as the wave-
length and intensity, and thus can be measured [153].
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A laser can also be created directly in a tissue by in-
jecting a fluorescent dye and using the scattering proper-
ties of the tissue to induce random lasing [44, 45]. Ran-
dom lasing occurs when light is trapped in the disordered
media, in this case tissue, by multiple scattering forming
closed-path optical resonators. Lasing has been achieved
in Rhodamine-6G-impregnated human colon, kidney [46],
and bovine heart tissue [154]; Rhodamine-800-infiltrated
bone tissue [155, 156]; and fluorescent anticancer-drug-
infiltrated rodent uterine tissues [157]. The typical output
spectrum and spatial profile of random lasers are highly
sensitive to the microstructure of the tissue. Random laser
emission frommore heterogeneous, disorganized, cancer-
ous tissue exhibited more spectral lines than healthy tis-
sues of the same organ [46, 157, 158]. The sensitivity of
laser output to scatterers was used to detect nanoscale de-
formations in bones [156] and stress responses of bovine
pericardium [154]. As the random lasing is sensitive to
the position of scatterers, this can be used to character-
ize mechanical properties of tissues. The shift in the spec-
tral peaks of the random lasing in bones that were sub-
ject to mechanical stress was used to measure nanoscale
deformations [156]. Further studies have been conducted
on softer tissues including bovine pericardium and the
sac containing the heart [154]. Spectral width of the ran-
dom lasing has been measured while the stress on the tis-
sue was increased up to 6 MPa. When the tissue is elon-
gated, the collagen fibrils are aligned, reducing the scat-
tering and, therefore, increasing the lasing linewidth.
5.2 Cell lasers
TheGFP or organic dyes at high concentration (>100 µM) in
the cytoplasm have been shown to provide sufficient gain
to generate laser light. In one study [48], a human cell ex-
pressing GFP was placed between two laser mirrors and
pumped with a nanosecond pulsed laser. At pump energy
levels above a few nanojoule, a clear laser output was ob-
served. The laser output spectra variedwith changes in the
cell size and refractive index, which may be used for cy-
tometry and basic studies of intracellular biological pro-
cesses. Stable GFP transfection can make the laser replen-
ish the gain medium, rendering it self-healing [50]. Fluo-
rescent dyes obviate theneed for genetic transfection [159].
A liquid droplet in the air can confine light by total in-
ternal reflection so that the light circulates in the droplet
forming whispering gallery modes (WGMs) [160]. Water
droplets encapsulating cells and gain dyes have shown
to support lasing [161]. While this kind of laser is entirely
composed of biocompatible materials for both cavity and
gain, the droplet easily breaks when made in contact with
tissue. Microdroplet lasers have been encapsulated in a
superhydrophobic biocompatible polymer matrix, which
renders them potentially implantable [145].
Cell lasers incorporating microresonators have been
demonstrated by using fluorescent beads with diameters
of about 10 µm (Fig. 9a, b) [47, 162, 163]. The WGM out-
put spectra allowed the individual bead diameters to be
determined with 50-pm precision, which can be used as a
unique identifier to tag a large number of cells and track
them. The position of modes was also used to sense the
change in refractive indexwithin the cell. Intracellular las-
ing was also demonstrated using dye-doped oil droplets
injected in cells (Fig. 9c,d). Lasing spectra from deformed
droplets was used to measure intracellular forces down
to 20 pN/µm2. An adipocyte, a fat cell, containing a large
lipid droplet was also used as a natural optical cavity sup-
porting lasing upon fluorescent dye staining and pumping
with external laser [47]. Adipocyte laserswere also demon-
strated inside fat tissue using an optical fiber for light de-
livery and collection. Injectable micro-bio-lasers offer a
new possibility of delivering light to tissues.
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Fig. 9. Intracellular micro-lasers. (A) An intracellular laser based
on a fluorescent bead. (B) Lasing emission from an 11.5-µm
bead in a cell. Scale bar, 10 µm. (C) A dye-doped high-index oil
droplet injected into a cell. (D) Lasing spectrum from a single oil
droplet shows split spectral lines because of droplet deformation.
Reprinted by permission from [47], Copyright 2015, Macmillan Pub-
lishers Ltd.
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6 Optoelectronic devices
While in this review we have discussed the development
of biomaterial-based devices, many existing medical de-
vices such as the pacemaker or cochlear implant contain
sophisticated electronic circuitry that are fully encapsu-
lated, usually with hermetic packaging, to facilitate im-
plantation into the body [71, 72]. The separation of active
electronic components from the body’s environment cre-
ates unique design challenges, including biocompatibility
of the packaging material, leakage of internal materials,
and particularly for batteryless devices, wireless powering
and communication [164]. Recent innovations in wireless
powering through radiofrequency (RF) harvesting has en-
abled miniaturization of devices [165] and delivery of mil-
liwatt levels of electrical power through over 5 cm of tis-
sue [74]. Optical devices could also follow this principle of
a sealed wireless capsule containing regular nonbiocom-
patible optical devices. Thesemay include any device such
as light sources (LED and laser), photodetectors including
cameras, and imaging devices such as microscope objec-
tive.We could also imagine thatmore complicated systems
such as optical coherence tomography (OCT), spectrome-
ter, and confocal microscopes could be implanted into the
body. The main limitation here is the size of the device,
which could benefit from advances in integrated optical
circuits. The light from such device could be coupled to the
tissue by using an optical window on the device or having
one or multiple optical fibers extending to different parts
of the body.
One example of suchdevice currently in use is the cap-
sule endoscopy [166]. Apill-sized camera is ingestedby the
patient and takes pictures of the intestine while it is travel-
ing through it. The camera contains a light source, batter-
ies, and antenna to transmit data. Typically, the small in-
testine is imaged in this way because it cannot be reached
by endoscopy or colonoscopy. There is no reason why a
similar device could be implanted into the body having
wireless power transfer for longer operational lifetime.
Other examples are implantable LEDs, which have
generated interest for biosensing, photothermal and pho-
todynamic therapy, and optogenetics [167–170]. Of partic-
ular interest has been optogenetic applications, which re-
quires integration of miniature light sources deep in the
brain to activate specific neurons [169]. Tomaximize capa-
bilities in vivo, functional requirements such as long life-
time, high brightness, small size, mechanical robustness,
and flexibilitymust bemetwhile avoiding cytotoxicity, im-
munogenicity, sensitization, and chronic toxicity. To date,
most conventional light sources implanted in vivo are inor-
ganic semiconductor LEDs, such as GaN LEDs, with emis-
sion spectra typically in the blue region.
6.1 Semiconductor LEDs
Light activation of photosensitive proteins such as chan-
nelrhodopsin for in vivo optogenetic applications is tra-
ditionally achieved by integration of inorganic semicon-
ductor LEDs to a cranial window in mice [171]. However,
the use of wired, externalized LEDs limits opportunities
for specific applications such as behavior studies for free-
moving animals [172]. Animal movement is restricted by
the length and contortion of the power cable, while the
bulky size and shape of LEDs limit targeting of deep tis-
sues. To solve these challenges, wireless andmicro-scaled
LEDs have been developed using wireless power transfer
and micro-scaled circuit designs. A major consideration
in the design of wireless LEDs is power supply, which is
typically transmitted through RF energy harvesting [169,
173] or inductive power [174]. In contrast, wirelessly con-
trolled LEDs use rechargeable batteries and communicate
via RFs [173]. The operation range of wirelessly controlled
LEDs (4 m) is longer than that of wirelessly powered LEDs
(~1–2 m). The average output intensity of wireless LEDs
is typically ~10 mW/mm2 [169, 173], which exceeds (up
to 10-fold) the minimum intensity necessary to stimulate
rhodopsins.
Wireless LEDs have been directly implanted to deep
brain tissues inmice [169, 174, 175]. Flexible and injectable
µ-LEDs, with dimensions 0.1 × 1 × 1 mm3 that are less
than 1000th the size of conventional LEDs, are suited
for chronic use in vivo because of their small sizes, ef-
fective thermal management, and reduced tissue dam-
age during the insertion process [169]. These LEDs have
shown stable performance for several months following
implantation [173]. However, wireless operation on freely
moving animals is only possible for short-term experi-
mentation, because a relatively large head-mounted wire-
less RF receiver is required. Another approach involves a
completely implantable wireless optogenetic system, in-
cluding the LED, RF power source, and controller (total
20mg, 10mm3), that canbe implanted throughout the ner-
vous system (Fig. 10a) [176]. Recently, miniaturized wire-
less optoelectronic systems with high mechanical compli-
ance have enabled implantation to previously inaccessible
anatomical locations, such as in the epidural space for il-
lumination of the spinal cord (Fig. 10b) [165].
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Fig. 10.Wireless LEDs for optogenetics. (A) Left: Schematic of completely implantable micro-LED system. Right: Mouse with subcutaneously
implanted micro-LED for stimulation of peripheral nerve endings. Reprinted by permission from [176], Copyright 2015, Macmillan Publishers
Ltd. (B) Left: Picture of a soft optoelectronic system including the harvester component and the soft, stretchable connector to an LED. Right:
Schematic of implantation of device into the epidural space for spinal illumination. Reprinted by permission from [165], Copyright 2015,
Macmillan Publishers Ltd.
6.2 Biomaterial based LEDs
In recent years, there has been great interest in using sus-
tainable, organic light-emitting diodes (OLEDs) for con-
sumer products such as flexible displays [177, 178]. Ow-
ing to their flexibility and organic constituents, OLEDs are
also attractive candidates for biomedical applications [22,
179]. OLEDs are flexible, easily scalable, and made of
organic materials. However, OLEDs are highly sensitive
to water and oxidation [180] and leaking of nonbiocom-
patible organic components could be potentially toxic
to the host. There are only a few reports using conven-
tional OLEDs in close contact with biological matter [181].
OLED are mostly used as wearable light sources [182–
184] and have not been implanted into tissue. Therefore,
there is a need for completely biocompatible and possi-
bly biodegradable LEDs: bio-OLEDs. To reach this goal,
all LED components—the substrate, electrodes, conduct-
ing and emissive layers—should be made of biomaterials.
To date, a number of individual LED components
made using biocompatible, organic materials have been
reported. For example, DNA was used as electron/hole
transport/blocking layer material [185–187] or as phos-
phorescent host [188] in OLED devices. Individual nucle-
obaseswere also used as electron/hole transport/blocking
layer material [189, 190]. In another study, silk fibroin was
used as gate dielectric in organic light-emitting transistor
(OLET) [191]. Two other necessary components of an OLED
are the substrate, which serves as a mechanical support,
and electrodes,which enable electrical contacts. As aflexi-
ble and biodegradable substrate, bacterial cellulose mem-
brane was used [192], exhibiting high transparency and
good mechanical strength. However, for the electrode, an
inorganic indium tin oxide (ITO) film was coated to the
cellulose membrane. Paper, also a cellulose material, has
been recently used for paper electronics [193] and is a po-
tential substrate material. Bio-OLEDs could also be inte-
grated with biomaterials-based electronics to create mul-
tifunctional implantable optoelectronic devices. Biocom-
patible electronics [194, 195] are a much larger and more
developed research area than biocompatible photonics.
For example, completely biodegradable transistors [196,
197] and other electronic components [22] have been de-
veloped. It is likely only a matter of time when the devel-
opment of bio-OLEDs will follow.
7 Future Perspectives
Diffraction gratings, photonic crystals, reflectors, and
plasmonic devices, which are commonly used for in vitro
sensing, have been fabricated with biocompatible mate-
rials. Significant advances have been made in the devel-
opment of biocompatible optical waveguides to deliver
and extract the light from the body as well as having bio-
functional components for sensing and therapy. As an
alternative to waveguides, light can be generated within
the body by bioluminescence or LED sources. Biolumines-
cence is a process that emits light from chemically stored
energy [198]. This naturalmechanism is optimized to func-
tion in biological systems and could be potentially applied
as a weak but natural light source in biocompatible opti-
cal devices. For higher optical intensities, biocompatible
LEDs and bio-lasers may be used. Energy can be provided
to the implanted light source wirelessly without physical
link to an external source. Alternatively, it would be ben-
eficial to power these and other photonic devices by in-
ternal sources of energy such as biomechanical, biother-
mal, and biochemical energy. It has been demonstrated
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that physiologic motions such as heart beating and respi-
ration can be transduced to electric energy by using piezo-
electric transducer [199]. Lasers are another class of light
sources that have been successfully integrated with cells
and tissues. Their narrow emission spectrum is especially
useful in sensing, spectroscopy, and imaging.
While the development of implantable biophotonic
devices for clinical applications is in its infancy, many
parallels can be drawn to the progress in implantable
cardiac pacemakers over the past 60 years. Spurred by
19th century observations that electrical impulses can con-
trol heart beating, early pacemakers were external [200],
including needle electrodes introduced directly into the
heart (1930s), bulky transcutaneous pacemakers powered
by AC power (1940s), and battery-operatedwearable pace-
makers (1950s), before the fully implantable pacemaker
was demonstrated in 1958 [201]. One key factor that en-
abled implantation was encasement of the battery and cir-
cuitry with epoxy resin and silicone rubber, which has
since been replaced with titanium because of its supe-
rior biocompatibility, reduction of electromagnetic inter-
ference, and stronger mechanical properties [202].
Today, the use of light for diagnostics, therapy, and
surgery is ubiquitous. The pulse oximeter,whichmeasures
the patient’s arterial oxygen saturation, is universally used
in emergencymedicine. Thewireless capsule endoscope is
routinely ingestedbypatients for imagingof theupper gas-
trointestinal tract. Emerging flexible optoelectronic tech-
nologies can be used forwearable healthmonitoring, such
as quantitative imaging of skin temperature and thermal
properties [203]. However, the vast majority of photonic
applications in the clinic requires use of external light
sources, limiting applications to superficial areas such as
the eye or skin. As the development of biocompatible pho-
tonic materials continues, implantable photonic devices
for human use are likely to emerge, enabling chronic sens-
ing and imaging of difficult to access locations such as the
brain [204, 205] and expanding therapeutic applications
such as low-level light therapy [206], blue-light antimicro-
bial treatment [207], and photodynamic therapy [208] be-
yond superficial skin to deep tissues. The ability to render
cells photoactive has opened opportunities for light-based
cell therapy and sensing, such as with optogenetics and
intracellular lasers. As compared to electrical stimulation
of cells, light–tissue interactions are decidedly more di-
verse anduse a rangeof photonicmaterials frompolymers,
semiconductors, organic molecules, and cells.
Small size and mechanical flexibility would be
strongly preferred for most applications of implanted de-
vices. The choice of the appropriate material for use in
vivowill depend not only on the functionality required but
also on its biocompatibility profile (Fig. 11). The ability of
the device, particularly those encapsulating cells, to inte-
grate into host tissue without impairing functionality and
harming the host needs to be evaluated. For chronically
implanted devices, FBR-resistant properties enabling long
implanted lifespans are essential. For devices implanted
for a relatively short time of operation or those that are
too small or dispersed, biodegradability and bioresorba-
bility can be implemented to avoid the need to harvest the
device after use.
Fig. 11. Factors to consider when designing implantable biophotonic
devices.
In principle, it should be possible to realize almost
any optical components and functions with biocompati-
ble materials, although biocompatibility may be achieved
at the expense of optical performance as compared to
conventional photonic technologies. Implantable optical
functionalities can serve as building blocks for more com-
plex devices and systems. Most studies conducted to date
have focused on proof-of-concept demonstrations on opti-
cal benches or animal studies. Further efforts are expected
to extend the concepts and techniques demonstrated to
date for practical applications in both preclinical and clin-
ical settings. We envision one day opening an optics prod-
uct catalog featuring a variety of implantable, biocompat-
ible components and devices.
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